|
Risk and Management of
Blood-Borne Infections in Health Care Workers
Elise M. Beltrami,1,* Ian T. Williams,2 Craig N. Shapiro,2 and
Mary E. Chamberland1
http://cmr.asm.org/cgi/content/full/13/3/385#SEC9
HIV Infections Branch, Hospital Infections Program,1 and
Hepatitis Branch, Division of Viral and Rickettsial Diseases,2
National Center for Infectious Diseases, Centers for Disease
Control and Prevention, Public Health Service, U.S. Department
of Health and Human Services, Atlanta, Georgia
SUMMARY
Exposure to blood-borne pathogens poses a serious risk to health
care workers (HCWs). We review the risk and management of human
immunodeficiency virus (HIV), hepatitis B virus (HBV), and
hepatitis C virus (HCV) infections in HCWs and also discuss
current methods for preventing exposures and recommendations for
postexposure prophylaxis. In the health care setting,
blood-borne pathogen transmission occurs predominantly by
percutaneous or mucosal exposure of workers to the blood or body
fluids of infected patients. Prospective studies of HCWs have
estimated that the average risk for HIV transmission after a
percutaneous exposure is approximately 0.3%, the risk of HBV
transmission is 6 to 30%, and the risk of HCV transmission is
approximately 1.8%. To minimize the risk of blood-borne pathogen
transmission from HCWs to patients, all HCWs should adhere to
standard precautions, including the appropriate use of hand
washing, protective barriers, and care in the use and disposal
of needles and other sharp instruments. Employers should have in
place a system that includes written protocols for prompt
reporting, evaluation, counseling, treatment, and follow-up of
occupational exposures that may place a worker at risk of
blood-borne pathogen infection. A sustained commitment to the
occupational health of all HCWs will ensure maximum protection
for HCWs and patients and the availability of optimal medical
care for all who need it.
INTRODUCTION
Exposure to blood-borne pathogens poses a serious risk to health
care workers (HCWs). Transmission of at least 20 different
pathogens by needlestick and sharps injuries has been reported
(79). Despite improved methods of preventing exposure,
occupational exposures will continue to occur.
Assessment of the risk of blood-borne pathogen transmission in
the health care setting requires information derived from
various sources, including surveillance data, studies of the
frequency and preventability of blood contacts, seroprevalence
studies among patients and HCWs, and prospective studies that
assess the risk of seroconversion after an exposure to infected
blood. Factors influencing the risk to an individual HCW over a
lifetime career include the number and types of blood contact
experienced by the worker, the prevalence of blood-borne
pathogen infection among patients treated by the worker, and the
risk of transmission of infection after a single blood contact.
In this article, we review the risk and management of the three
blood-borne viruses most commonly involved in occupational
transmission: human immunodeficiency virus (HIV), hepatitis B
virus (HBV), and hepatitis C virus (HCV). We also will discuss
current methods of preventing exposure, including standard
precautions and the use of safety devices in the health care
setting, as well as recommendations for postexposure
prophylaxis.
TRANSMISSION OF BLOOD-BORNE PATHOGENS IN THE HEALTH CARE SETTING
Modes of Blood-Borne Pathogen Transmission
In the health care setting, blood-borne pathogen transmission
occurs predominantly by percutaneous or mucosal exposure of
workers to the blood or body fluids of infected patients.
Occupational exposures that may result in HIV, HBV, or HCV
transmission include needlestick and other sharps injuries;
direct inoculation of virus into cutaneous scratches, skin
lesions, abrasions, or burns; and inoculation of virus onto
mucosal surfaces of the eyes, nose, or mouth through accidental
splashes. HIV, HBV, and HCV do not spontaneously penetrate
intact skin, and airborne transmission of these viruses does not
occur.
Epidemiology of Blood Contact
To understand the nature, frequency, and prevention of
percutaneous injuries and mucocutaneous blood contacts among
HCWs, prospective observational studies have been performed in
different patient care settings (Table 1). The percentage of
procedures with at least one blood contact of any type ranged
from 3% of procedures performed by invasive radiology personnel
in a study in Dallas, Tex. (130), to 50% of procedures performed
by surgeons in a study in Milwaukee, Wisc. (224). The percentage
of procedures with at least one injury caused by a sharp
instrument also varied widely, from 0.1 to 15%. These
differences may be related to variations in study methods,
procedures observed, and precautions used by the workers
performing the procedures.
|
TABLE 1. Prospective observational studies of
blood contact among HCWs |
|
|
|
Specialty and authors (reference) |
Yr |
Location(s) |
No. of procedures observed |
No. of procedures with 1
blood contact |
% Procedures with 1
sharps injury |
|
|
|
Surgery |
|
|
|
|
|
|
Tokars et al. (256) |
1990 |
New York, N.Y.; Chicago, Ill. |
1,382 |
46.6 |
6.9 |
|
Popejoy et al. (220) |
1988 |
Albuquerque, N.Mex. |
684 |
27.8 |
3.1 |
|
Quebbeman et al. (224) |
1990 |
Milwaukee, Wisc. |
234 |
50.4 |
15.4 |
|
Gerberding et al. (116) |
1988 |
San Francisco, Calif. |
1,307 |
6.4 |
1.3 |
|
Panlilio et al. (208) |
1988-1989 |
Atlanta, Ga. |
206 |
30.1 |
4.9 |
|
Obstetrics |
|
|
|
|
|
|
Panlilio et al. (210) |
1989 |
Atlanta, Ga. |
230 |
32.2 |
1.7 |
|
Invasive radiology |
|
|
|
|
|
|
Hansen et al. (130) |
1992 |
Dallas, Tex. |
501 |
3.0 |
0.6 |
|
Emergency room |
|
|
|
|
|
|
Marcus et al. (178) |
1989 |
New York, N.Y.; Chicago, Ill.;
Baltimore, Md. |
9,793 |
3.9 |
0.1 |
|
Dentistry |
|
|
|
|
|
|
Cleveland et al. (77) |
1993 |
New York, N.Y. |
16,340 |
NAa |
0.1 |
|
|
|
a
NA, not available. |
TABLE 1. Prospective observational studies of blood contact
among HCWs
Several of these studies assessed specific risk factors for
injury or exposure. For example, of the 99 percutaneous injuries
observed by Tokars et al. during 1,382 operations in five
different surgical specialties (general, orthopedic,
gynecologic, trauma, and cardiac), most (73%) were related to
suturing (256). Rates were highest (10%) during gynecologic
surgeries (256). Panlilio et al. found in their study of blood
contacts during surgery that risk factors for blood contacts by
surgeons included performing an emergency procedure, patient
blood loss greater than 250 ml, and surgery duration greater
than 1 h (208). In their study of dental procedures, Cleveland
et al. found that most percutaneous injuries sustained by dental
residents occurred extraorally and were associated with denture
impression procedures (77).
Retrospective studies and surveys have also shown high rates of
blood contact among HCWs in different patient care settings.
Tokars et al. found that among 3,420 participants at the
American Academy of Orthopaedic Surgeons annual meeting, 87.4%
of surgeons surveyed reported a blood-skin contact and 39.2%
reported a percutaneous blood contact in the previous month
(258). In a retrospective survey by O'Briain in 1991 (202), 56%
of 36 resident and staff pathologists reported that they had
sustained a cut or needlestick injury in the preceding year. In
this study, pathologists reported 72 injuries, corresponding to
a rate of one injury for every 37 autopsies performed and one
injury for every 2,629 surgical specimens handled (202). An
anonymous national survey of certified nurse-midwives by Willy
et al. found that 74% had soiled their hands with blood, 51% had
splashed blood or amniotic fluid in their faces, and 24% had
sustained one or more needlestick injuries in the preceding 6
months (281). Among 550 medical students and residents in Los
Angeles, Calif., who were surveyed anonymously by O'Neill et
al., 71% reported exposures to patients' blood and body fluids
during the preceding year (204). In a recent study of third- and
fourth-year medical students in San Francisco, Calif., by Osborn
et al., 12% reported an exposure to infectious body substances
over the 7-year study period, from 1990 to 1996 (205). There is
evidence among some groups of HCWs, such as dentists, that rates
of exposure are decreasing over time, temporally associated with
increased awareness and compliance with the practice of standard
precautions (76).
DETECTION AND DIAGNOSIS OF BLOOD-BORNE PATHOGEN INFECTIONS
An understanding of the detection and diagnosis of HIV, HBV, and
HCV infection is vital for the appropriate management and care
of HCWs exposed to or infected with bloodborne viruses.
Detection and Diagnosis of HIV Infection
After initial primary infection with HIV, there is a window
period prior to the development of detectable antibody. In
persons with known exposure dates, the estimated median time
from initial infection to the development of detectable antibody
is 2.4 months; 95% of individuals develop antibodies within 6
months of infection (34). Among HCWs with a documented
seroconversion to HIV, 5% tested negative for HIV antibodies at
>6 months after their occupational exposure but were
seropositive within 12 months (73). The two antibody tests
commonly used to detect HIV are the enzyme immunoassay (EIA) and
the Western blot. An HIV test result is reported as negative
when the EIA result is negative. The result is reported as
positive when the EIA result is repeatedly reactive and when the
result of a more specific, supplemental confirmatory test, such
as the Western blot, is also positive. Once an individual
develops an antibody response, it usually remains detectable for
life. HIV infection for longer than 6 months without detectable
antibody is uncommon (73, 226).
Direct virus assays (e.g., PCR for HIV RNA) are sensitive
methods for the detection of HIV infection. However, problems
with laboratory contamination, false-positive rates, and
increased costs limit their routine use. While PCR for HIV RNA
is approved for use in established HIV infection, its
reliability in detecting very early infection has not been
determined (34). At present, the false-positive and
false-negative rates of PCR are too high to warrant a broader
role for it in routine postexposure management (207).
Detection and Diagnosis of HBV Infection
The incubation period for acute hepatitis B ranges from 45 to
160 days, with an average of 120 days. Exposure to HBV can lead
to an acute infection which may result in a chronic infection.
Acute hepatitis B resembles other forms of viral hepatitis and
cannot be distinguished based on history, physical examination,
or serum biochemical tests.
The diagnosis of acute HBV infection is confirmed by the
demonstration in serum of hepatitis B surface antigen (HBsAg),
which appears well before onset of symptoms and before
development of antibody to hepatitis B core antigen (anti-HBc),
and immunoglobulin M (IgM) antibody to HBc, which appear at
approximately the same time as symptoms (143). The presence of
IgM anti-HBc indicates recent HBV infection, usually within the
preceding 4 to 6 months. The presence of hepatitis B e antigen (HBeAg)
in serum correlates with HBV replication, high titers of HBV,
and infectivity. Persons who are positive for HBeAg typically
have 108 to 109 HBV particles per ml of blood (243). In persons
who resolve acute HBV infection, antibody to HBsAg (anti-HBs)
develops and indicates immunity. The persistence of HBsAg for 6
months after the diagnosis of acute HBV is indicative of
progression to chronic HBV infection.
HBV serologic markers in different stages of infection and
convalescence are summarized in Table 2. Anti-HBc indicates
prior infection and lasts indefinitely. In persons who respond
to the hepatitis B vaccine, anti-HBs is the only antibody that
is elicited. Persons with chronic infection who have mutations
in the precore region of the HBV genome that prevent the
expression of HBeAg but allow the expression of infectious virus
have been described (40, 260). High titers of HBsAg can be
observed in these persons even though they are HBeAg negative.
The prevalence of these precore mutations in persons in the
United States is unknown. The prevalence may be relatively high
in certain parts of the world (41, 124, 171, 173, 197).
|
TABLE 2. HBV serologic markers in
different stages of infection and
convalescence (201a)a
|
|
|
|
Stage of infection |
HBsAg |
Anti-HBs |
Anti-HBc
|
HBeAg |
Anti-HBe |
|
Totalb |
IgM |
|
|
|
Late incubation period |
+ |
 |
 |
 |
+ or  |
|
|
Acute hepatitis B |
+ |
 |
+ |
+++ |
+ |
|
|
HBsAg carrier |
+ |
(+ rarely) |
+ |
 |
+ or  |
+ or |
|
Recent (<6 months; resolved
infectionc) |
 |
++ |
++ |
+ |
 |
+ or |
|
Distant (>6 months;
resolved infectionc) |
 |
++ |
++ |
 |
 |
+ or |
|
Vaccinated |
 |
++ |
 |
 |
 |
 |
|
|
|
a
+, positive; ++, strongly positive; +++, very
strongly positive; + or ,
variable reaction; ,
negative. |
|
b
The total anti-HBc assay detects both IgM and
IgG antibody. |
|
c
Resolved, the patient no longer has the disease.
|
|
TABLE 2. HBV serologic markers in different stages of infection
and convalescence (201a)a
Detection and Diagnosis of HCV Infection
The incubation period for acute HCV infection ranges from 2 to
24 weeks, with an average of 6 to 7 weeks (166, 179; L. B. Seef,
Letter, Ann. Intern. Med. 115:411, 1991). Because different
types of viral hepatitis are indistinguishable based on clinical
symptoms alone, serologic testing (Table 3) is necessary to
establish a specific diagnosis of hepatitis C (121). Screening
EIA and supplemental immunoblot assays are licensed and
commercially available to detect antibodies to HCV (anti-HCV)
(283). Because the rate of false positivity for the screening
EIA is high in many populations, including HCWs, supplemental
immunoblot assays must be used to judge the validity of
repeatedly reactive EIA results. Anti-HCV may be detected within
5 to 6 weeks after the onset of infection and remains detectable
long after the primary infection. In general, the interpretation
of serologic tests for anti-HCV is limited by the following
factors: (i) assays for anti-HCV do not distinguish between
acute, chronic, or past infection; (ii) in acute infection there
may be a prolonged interval between onset of illness and anti-HCV
seroconversion (though most infected individuals seroconvert
within 3 months of exposure); and (iii) the detection of anti-HCV
does not necessarily indicate active HCV replication (8).
|
TABLE 3. Tests for HCV infectiona
|
|
|
|
Test and type |
Description |
Application(s) |
Comments |
|
|
|
Anti-HCV |
EIA and supplemental assay
(i.e., recombinant immunoblot assay [RIBA]) |
Indicates past or present
infection but does not differentiate between
acute, chronic, or resolved infection; all
positive EIA results should be verified by a
supplemental assay |
Sensitivity 97%;
EIA alone has low positive predictive value in
low-prevalence populations |
|
HCV RNA |
|
|
|
|
Qualitative testsb,c |
Reverse transcriptase PCR (RT-PCR)
amplification of HCV RNA by in-house or
commercial assays (e.g., Amplicor HCV) |
Detects presence of
circulating HCV RNA; for monitoring patients on
antiviral therapy |
Detects virus as early as
1-2 weeks after exposure; detection of HCV RNA
during course of infection may be intermittent
(a single negative RT-PCR result is not
conclusive); false-positive and false-negative
results might occur |
|
Quantitative testsb,c |
RT-PCR amplification of HCV
RNA by in-house or commercial assays (e.g.,
Amplicor HCV Monitor); branched-chain DNA assays
(e.g., Quantiplex HCV RNA Assay) |
Determines concentration of
HCV RNA; may be useful for assessing the
likelihood of response to antiviral therapy |
Less sensitive than
qualitative RT-PCR; should not be used to
exclude the diagnosis of HCV infection or to
determine treatment endpoint |
|
Genotypingb,c |
Several methodologies
available (e.g., hybridization, sequencing) |
Groups isolates of HCV
based on genetic differences into six genotypes
and >90 subtypes; with new therapies, length of
treatment may vary based on genotype |
Genotype 1 (subtypes 1a and
1b) most common in United States and associated
with lower response to antiviral therapy |
|
Serotypingb |
EIA based on
immunoreactivity to synthetic peptides (e.g.,
Murex HCV Serotyping 1-6 Assay) |
No clinical utility |
Cannot distinguish between
subtypes; dual infections often observed |
|
|
|
a
Adapted from reference 64a. |
|
b
Currently not FDA approved; lack
standardization. |
|
c
Samples require special handling (e.g., serum
must be separated within 2 to 4 h of collection
and stored frozen [ 20 or 70°C];
samples should be shipped on dry ice). |
|
TABLE 3. Tests for HCV infectiona
HCV RNA can be detected in serum or plasma within 1 to 2 weeks
of exposure to the virus and several weeks before onset of
alanine aminotransferase (ALT) elevations or the appearance of
anti-HCV (103). In patients with chronic HCV infection, HCV RNA
levels may remain relatively stable or can fluctuate over
1,000,000-fold. Fluctuations in HCV RNA may or may not correlate
with elevations in transaminase levels. Rarely, the detection of
HCV RNA may be the only evidence of HCV infection (14).
PCR techniques to amplify reverse-transcribed cDNA are currently
the most sensitive methods for detecting HCV RNA. Both
qualitative (122) and quantitative (87, 229) methods can be used
to detect HCV RNA. Quantitative assays are less sensitive than
qualitative assays and should not be used as a primary test to
confirm or exclude the diagnosis of HCV infection (212).
Currently, testing for HCV RNA is available on a research basis
and no tests have been approved by the U.S. Food and Drug
Administration. Because of assay variability, results of HCV RNA
testing should be interpreted cautiously.
There are at least six different genotypes and more than 90
subtypes of HCV (33). About 70% of HCV-infected persons in the
United States are infected with genotype 1; subtype 1a
predominates over subtype 1b. Several different nucleic acid
detection methods are commercially available to group isolates
of HCV based on genotypes and subtypes (172).
RISK OF OCCUPATIONAL TRANSMISSION OF HIV FROM PATIENTS TO
WORKERS
Risk of HIV Infection Postexposure
Prospective studies of HCWs have estimated that the average risk
for HIV transmission after a percutaneous exposure to
HIV-infected blood is approximately 0.3% (95% confidence
interval = 0.2 to 0.5%) (23) and that after a mucous membrane
exposure it is 0.09% (95% confidence interval = 0.006 to 0.5%)
(147). The risk after a cutaneous exposure is less but has not
been well quantified since no HCW enrolled in a prospective
study has seroconverted after an isolated skin exposure. There
are insufficient data to quantify the risk of transmission after
occupational exposure to potentially infectious tissues or
fluids other than blood. However, in a study by Fahey et al.,
none of 559 participants reporting cutaneous exposures to blood,
sputum, urine, feces, or other body substances from patients
presumed infected with HIV acquired HIV infection (102). There
is also no evidence of a risk for HIV transmission by the
aerosol route. Transmission of HIV by aerosol would require the
generation of aerosolized particles of blood, the presence of
infective HIV in these aerosolized particles, and the deposition
of a sufficient number of infective particles in the respiratory
tract or on the mucous membranes of a susceptible host to cause
infection. Biological or epidemiologic evidence that HIV can be
transmitted by aerosols via the respiratory route currently does
not exist (22). Although not specifically designed to assess the
possibility of aerosol transmission of HIV, the 1991
seroprevalence survey of attendees of the annual meeting of the
American Academy of Orthopaedic Surgeons addressed this concern
indirectly (258). There were 1,201 study participants without
nonoccupational risk factors who had participated in procedures
on patients with HIV infection or AIDS and had never used a
"space suit" or other device to prevent inhalation of aerosols.
Since power instruments are used frequently in orthopedic
procedures, many of these participants may have been exposed to
blood or tissue aerosols produced by these instruments; all were
HIV seronegative (258).
The risk of HIV transmission after a percutaneous exposure
appears to be influenced by several factors. To assess possible
risk factors, the Centers for Disease Control and Prevention
(CDC), in collaboration with international public health
authorities, conducted a retrospective case-control study using
data reported to national surveillance systems in the United
States, France, Italy, and the United Kingdom. Based on logistic
regression analysis, factors associated with HIV transmission
after percutaneous exposure included a deep injury, a device
visibly contaminated with the source patient's blood, procedures
involving a needle placed directly in the patient's vein or
artery, and a source patient who died from AIDS within 60 days
of the exposure (39). The findings of the case-control study
suggest that the risk for HIV infection likely exceeds 0.3% for
percutaneous injuries involving a larger volume of blood and/or
higher titer of HIV in the blood. Several laboratory studies
support these findings. In vitro models have shown that
increasing needle size and penetration depth are associated with
increased blood transfer volume (182), that hollow-bore needles
transfer greater volumes of blood than solid suture needles, and
that gloves reduce the amount of blood transferred (26). Studies
also have shown that the level of infectious HIV present in the
blood of most patients with symptomatic AIDS is significantly
higher than the level present in patients with asymptomatic HIV
infection (141). An additional finding of the case-control study
was that postexposure use of zidovudine (ZDV) by HCWs was
associated with a lower risk for HIV transmission (39). (This
issue will be discussed in more detail in the section
Postexposure Chemoprophylaxis for HIV [below]). It is also
possible that host defense mechanisms influence the risk of HIV
transmission. One study demonstrated an HIV-specific T-helper
cellular immune response when peripheral blood mononuclear cells
from a small number of HCWs exposed to HIV were stimulated in
vitro by HIV. None of the HCWs seroconverted. One possible
explanation for these observations is that host immune responses
prevented establishment of HIV infection after exposure (75).
Similar cytotoxic T-lymphocyte responses have been observed in
other populations with repeated HIV exposure without resulting
infection (70, 74, 160, 170, 225).
HIV Seroprevalence among Patients
In the United States, HIV seroprevalence rates vary widely by
geographic area and patients' demographic characteristics. The
CDC's Sentinel Hospital Surveillance System tested 195,829
anonymous patient blood samples at 20 hospitals in 15 cities
between September 1989 and October 1991. The HIV seroprevalence
at these institutions ranged from 0.2 to 14.2% and was highest
among men aged 25 to 44 years and patients with infectious
conditions (excluding symptomatic HIV infection) and
drug-related conditions (153).
Similarly, seroprevalence data for unselected hospital
admissions and for patients presenting to emergency departments,
operating rooms, and obstetrical units have demonstrated
considerable variation (Table 4). The lowest seroprevalence
rates have been reported in rural and suburban areas: 0.15%
among trauma patients in Wichita, Kans. (190), and 0.4% among
elective surgery patients in suburban Baltimore, Md. (68). The
highest seroprevalence rates have been reported in urban,
inner-city populations: 5.2 to 6.0% among emergency department
patients in inner-city Baltimore, Md. (157, 191), and 5.5% among
non-obstetric hospitalized patients in Denver, Colo. (K.
Krasinski, W. Borkowski, D. Bebenroth, and T. Moore, Letter, N.
Engl. J. Med. 318:185, 1988).
|
TABLE 4. HIV seroprevalence in
emergency, hospital, surgery, and
obstetrics patients |
|
|
|
Authors (reference) |
Yr |
Setting |
Location |
No. of patients tested |
No. of patients HIV positive (%) |
|
|
|
Kelen et al. (158) |
1987 |
Emergency department |
Baltimore, Md. |
2,302 |
119 (5.2) |
|
Kelen et al. (157) |
1988 |
Emergency department |
Baltimore, Md. |
2,544 |
152 (6.0) |
|
Marcus et al. (178) |
1989 |
Emergency department |
Six high-AIDS areas |
20,382 |
a
|
|
Nagachinta et al. (191) |
1990 |
Emergency department |
Los Angeles, Calif. |
1,945 |
40 (2.1) |
|
Mullins and Harrison (190) |
1987-1991 |
Trauma center |
Wichita, Kans. |
2,004 |
3 (0.15) |
|
Gordin et al. (119) |
1987 |
Hospital |
Washington, D.C. |
616 |
23 (3.7) |
|
Trepka et al. (261) |
1993 |
Hospital |
Denver, Colo. |
2,825 |
155 (5.5) |
|
Charache et al. (68) |
1989 |
Elective surgery |
Baltimore, Md. |
4,087 |
18 (0.4) |
|
Montecalvo et al. (187) |
1992 |
Surgery-obstetrics |
Valhalla, N.Y. |
1,056 |
15 (1.4) |
|
Krasinsi et al.b
|
1986-1987 |
Obstetrics |
New York, N.Y. |
1,192 |
28 (2.4) |
|
Donegan et al. (94) |
1987-1990 |
Obstetrics |
Boston, Mass. |
3,845 |
93 (2.4) |
|
|
|
a
4.1 to 8.9 patients per 100 patient visits. |
|
b
K. Krasinski, W. Borkowsky, D. Bebenroth, and
T. Moore, Letter, N. Engl. J. Med. 318:185,
1988. |
|
TABLE 4. HIV seroprevalence in emergency, hospital, surgery,
and obstetrics patients
In a CDC study conducted in six emergency departments in three
urban and three suburban areas of New York, N.Y., Chicago, Ill.,
and Baltimore, Md., the overall rate of HIV infection ranged
from about 4 to 9 per 100 patient visits (178). The study found
that many patients' HIV infections were unrecognized at the time
of initial presentation to the hospital. The percentage of
patients whose HIV infection was unknown to hospital emergency
department workers was about 70% in the three inner city
hospitals and ranged from 40 to 90% in the three suburban
hospitals.
Incidence of Occupationally Acquired HIV Infection
As of 30 June 1999, a total of 191 U.S. workers had been
reported to the CDC's national surveillance system for
occupationally acquired HIV infection (Table 5) (65). Fifty-five
HCWs had known occupational HIV exposures, with a baseline
negative HIV test and subsequent documented seroconversion.
Fifty of these exposures were to HIV-infected blood, one was to
visibly bloody fluid, one was to an unspecified fluid, and three
were to concentrated virus in a laboratory. Of the 55 HCWs, 47
sustained percutaneous exposures, 5 had mucocutaneous exposures,
2 had both a percutaneous and a mucocutaneous exposure, and 1
had an unknown route of exposure. Twenty-five of these HCWs have
developed AIDS.
|
TABLE 5. HCWs with documented and
possible occupationally acquired HIV infection
reported through June 1999 in the United Statesa
|
|
|
|
Occupation |
No. of documented cases of occupational
transmission |
No. of possible cases of occupational
transmission |
|
|
|
Dental worker, including
dentist |
|
6 |
|
Embalmer or morgue
technician |
1 |
2 |
|
Emergency medical
technician or paramedic |
|
12 |
|
Health aide or attendant |
1 |
15 |
|
Housekeeper or maintenance
worker |
1 |
12 |
|
Laboratory technician,
clinical |
16 |
16 |
|
Laboratory technician,
nonclinical |
3 |
|
|
Nurse |
23 |
34 |
|
Physician, nonsurgical |
6 |
12 |
|
Physician, surgical |
|
6 |
|
Respiratory therapist |
1 |
2 |
|
Technician, dialysis |
1 |
3 |
|
Technician, surgical |
2 |
2 |
|
Technician or therapist,
other |
|
10 |
|
Other health care
occupations |
|
4 |
|
Total |
55 |
136 |
|
|
|
a
HCWs are defined as those persons, including
students and trainees, who have worked in a
health care, clinical, or HIV laboratory setting
at any time since 1978. Adapted from reference
65. |
|
TABLE 5. HCWs with documented and possible occupationally
acquired HIV infection reported through June 1999 in the United
Statesa
Of the 191 U.S. workers reported to the CDC's surveillance
system, 136 have been reported as possible cases of
occupationally acquired HIV infection. None of these HCWs
reported behavioral or blood transfusion risk factors, and all
reported occupational exposures to blood, body fluids, or
laboratory specimens containing HIV. However, the time or source
of infection was undocumented, usually because no baseline serum
sample was available to establish seronegativity at the time of
exposure.
The CDC's surveillance system likely does not reflect the full
extent of occupationally acquired HIV infection because of
underreporting of known infections or underrecognition of HIV
infection. Studies of HCWs in hospital settings suggest that
many percutaneous injuries are not reported (129, 177). Also,
HCWs may not complete postexposure follow-up serologic testing
(D. Cardo and the Health Care Worker Surveillance Study Group,
Abstr. 6th Annu. Meet. Soc. Healthcare Epidemiol. Am., abstr.
67, 1996).
HIV Seroprevalence Surveys among HCWs
HIV seroprevalence surveys provide a way of indirectly assessing
the risk of occupationally acquired HIV infection. The CDC has
conducted two voluntary anonymous seroprevalence surveys of
surgeons in different specialties. In 1992, a seroprevalence
survey was done among general surgeons, obstetricians,
gynecologists, and orthopedic surgeons practicing in moderate to
high AIDS incidence areas. Of the 770 participating surgeons,
one general surgeon, who reported nonoccupational risk factors
for HIV infection on an anonymous questionnaire, was HIV
positive (209). In 1991, a seroprevalence survey was done among
surgeons attending the annual meeting of the American Academy of
Orthopaedic Surgeons. Of the 3,420 participants, two surgeons,
both of whom reported nonoccupational risk factors, were HIV
positive (258). Other seroprevalence studies similarly have
shown low rates of HIV seropositivity among HCWs without
nonoccupational risk factors for HIV infection (Table 6) (20,
66, 71, 80, 82, 107, 117, 118, 123, 163, 215, 264; P. Ebbensen,
M. Melbye, F. Scheutz, A. J. Bodner, and R. J. Bigger, Letter,
JAMA 256:2199, 1986; C. Siew, S. E. Gruninger, and S. A. Hojvat,
Letter, N. Engl. J. Med. 318:1400-1401, 1988).
|
TABLE 6. Published HIV seroprevalence
in selected HCWs |
|
|
|
Occupation and authors (reference) |
No. of HCWs tested |
No. of HCWs HIV positive |
% Prevalence |
|
|
|
Surgeon |
|
|
|
|
Panlilio et al. (209) |
770 |
1 |
0.13 |
|
Tokars et al. (258) |
3,420 |
2 |
0 |
|
HCW blood donor |
|
|
|
|
Chamberland et al. (66) |
9,449 |
3 |
a
|
|
U.S. Army Reserve
physician, dentist |
|
|
|
|
Cowan et al. (82) |
3,347 |
3 |
Not known |
|
Dentist |
|
|
|
|
Flynn et al. (107) |
89 |
0 |
0 |
|
Klein et al. (163) |
1,132b |
1 |
0.09 |
|
Siew et al.c |
1,195 |
0 |
0 |
|
Gruninger et al. (123) |
1,165 |
1 |
0.09 |
|
Gruninger et al. (123) |
1,433b |
0 |
0 |
|
Gruninger et al. (123) |
1,429b |
0 |
0 |
|
Ebbesen et al.d |
961 |
0 |
0 |
|
Hemodialysis staff |
|
|
|
|
Assogba et al. (20) |
40 |
0 |
0 |
|
Chirgwin et al. (71) |
25 |
0 |
0 |
|
Comodo et al. (80) |
84 |
0 |
0 |
|
Goldman et al. (118) |
49 |
0 |
0 |
|
Peterman et al. (215) |
161 |
2 |
1.2 |
|
Mortician, embalmer |
|
|
|
|
Gershon et al. (117) |
130 |
1 |
0.8 |
|
Turner et al. (264) |
129b |
0 |
0 |
|
|
|
a
One HCW lost to follow-up. |
|
b
Persons with nonoccupational risk excluded. |
|
c
C. Siew, S. E. Gruninger, and S. A. Hojvat,
Letter, N. Engl. J. Med. 318:1400-1401,
1988. |
|
d
P. Ebbesen, M. Melbye, F. Scheutz, A. J. Bodner,
and R. J. Bigger, Letter, JAMA 256:2199,
1986. |
|
TABLE 6. Published HIV seroprevalence in selected HCWs
One limitation of seroprevalence studies is that the extent of
occupational and nonoccupational exposure to HIV among tested
workers is usually unknown. Also, the rates may be
underestimates if individuals deferred testing because they knew
they were or suspected they might be HIV positive. Nonetheless,
these seroprevalence surveys indicate that there was not a high
rate of undetected HIV infection among the HCWs studied, many of
whom had substantial opportunity for occupational exposures.
RISK OF OCCUPATIONAL TRANSMISSION OF HBV FROM PATIENTS TO
WORKERS
Risk of HBV Infection Postexposure
The probability of HBV transmission after an occupational
exposure is dependent upon the concentration of infectious
virions in the implicated body fluid, the volume of infective
material transferred, and the route of inoculation (e.g.,
percutaneous or mucosal).
HBV is present in high titers in blood and serous fluids,
ranging from a few virions to 109 virions per ml (142). The
virus is present in moderate titers in saliva, semen, and
vaginal secretions (154). The titer in semen and saliva is
generally 1,000 to 10,000 times lower than the corresponding
titer in serum (44, 269). Other body fluids such as urine and
feces contain very low levels of HBV unless contaminated with
blood (91, 106, 149).
One of the most common modes of HBV transmission in the health
care setting is an unintentional injury of an HCW from a needle
contaminated with HBsAg-positive blood from an infected patient
(5). The average volume of blood inoculated during a needlestick
injury with a 22-gauge needle is approximately 1 µl (V. M.
Napoli and J. E. McGowan, Letter, J. Infect. Dis. 155:828,
1987), a quantity sufficient to contain up to 100 infectious
doses of HBV (243). The risk of transmission after a needlestick
exposure to a nonimmune person is at least 30% if the source
patient is HBeAg positive but is less than 6% if the patient is
HBeAg negative (17, 120, 277). Blood from patients with HBsAg
titers below the threshold of detection using routine serologic
tests is rarely infectious (4). While overt percutaneous
injuries are efficient modes of HBV transmission, other
less-obvious exposures may also lead to occupationally acquired
HBV infection. In a case series of HBV-infected HCWs, fewer than
10% recalled a specific percutaneous injury, while 29 to 38%
recalled caring for an HBsAg-positive patient within 6 months
prior to their onset of illness (35; A. K. R. Chaudhuri and E.
A. C. Follet, Letter, Br. Med. J. 284:1408, 1982).
HBV Seroprevalence among Patients
The risk of acquiring HBV is related to the prevalence of HBV
infection in the patient population with which the HCW works.
Patients who are HBsAg positive, either from acute or chronic
infection, are potential sources of infection. Patients who are
|